Searching for novel multimodal treatments in oligometastatic pancreatic cancer

BACKGROUND: Metastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients with oligometastatic disease could benefit from multimodal treatments connecting chemotherapy and surgical treatment or radiofrequency ablation (RFA) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippini, D. M., Grassi, E., Palloni, A., Carloni, R., Casadei, R., Ricci, C., Serra, C., Ercolani, G., Brandi, G., Di Marco, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106565/
https://www.ncbi.nlm.nih.gov/pubmed/32228504
http://dx.doi.org/10.1186/s12885-020-06718-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106565/
https://www.ncbi.nlm.nih.gov/pubmed/32228504
http://dx.doi.org/10.1186/s12885-020-06718-3

Ejemplares similares